Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Robust Gold, Silver Projects & Promising Drill Results

(Click to play video.) Affinity Metals Corp. ( TSX-V: AFF , Forum ) is focused on the acquisition, exploration, and development of strategic metal deposits within North America. Affinity is following a hybrid approach of combining the advancement of stra...

Kardashian-Style News Bomb: Already Big Ashram Gets Bigger And Bigger

Bigger is Better (at least in this respect) What a pleasant surprise! The Ashram Rare Earth and Fluorspar Deposit continues to grow. As announced today by Commerce Resources Corp. , recent core assays for vertical drilling at Ashram has disc...

Klondike Golden Moments

Foreword: This tale grew from a chance nugget discovery along the shore of a humble Yukon creek carving through the remote Territory and became the great history of the Klondike Gold Rush. Join author James Kwantes as he touches down in the Yukon with 12 exciting stories and c...

Sarepta Shares Get a 35% Boost from FDA Approval of 2nd DMD Drug

Sarepta Therapeutics shares traded 35% higher after the firm reported that the FDA approved its second RNA exon-skipping treatment drug VYONDYS 53 injection for the treatment of Duchenne's Muscular Dystrophy in patients amenable to skipping Exon 53. Yesterday evening,...

June 26th 2020, Silver Chartbook – Silver let it ride

Silver let it ride Time relativity errors occur typically after long established sideways ranges. Meaning you get out too early of your trade. You waited a long time to finally be in your desired trade and even though everything goes perfect you want out really badly. The...

Westhaven’s robust economics are a solid foundation to expand gold-silver inventory

In the heart of British Columbia, a new study has illuminated a high-grade gold project with immense potential right off a highway. The findings indicate a compelling low-cost, high-margin opportunity that has captured the attention of investors seeking exceptional return...

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $...

Searching for the most promising non-U.S. investment options

When scanning the various investment boards and forums on the Internet these days, it's obvious that most people have very low confidence both in the economy and the government's efforts to fix it. "Smoke and mirrors" is a common theme directed at the officials wh...

New Pacific Metals delivers robust Silver Sand pre-feasibility study

Project with post-tax NPV of $740M and IRR of 37% By Francois Kalos New Pacific Metals Corp. ( TSX:NUAG; NYSE-A:NEWP ) has delivered a strong pre-feasibility study (PFS) for its Silver Sand silver project in Potosi, Bolivia. The PFS is consistent with the r...

Scoping Study for U.S. Lithium Project Confirms 'Robust Economics'

The pros and cons of the parameters outlined within it were addressed in a ROTH Capital Partners report. In an Aug. 8 research note, ROTH Capital Partners analyst Joe Reagor reported that Piedmont Lithium Ltd.'s (PLL:NASDAQ; PLL:ASX) updated scoping study for its No...
1 2 3 4 5 6 7 8 9 10 ...